Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05256199
Other study ID # 2021.0220
Secondary ID NL77242.029.21
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 24, 2022
Est. completion date June 1, 2025

Study information

Verified date January 2024
Source Alzheimercentrum Amsterdam
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

FINGER-NL is a multi-center, randomized, controlled, multidomain lifestyle intervention trial among 1,206 older adults at risk for cognitive decline with a duration of 24 months. Participants are randomized in a 1:1 ratio to a personalized multi-domain lifestyle intervention (high-intensity intervention group) versus online access to general lifestyle-related health information (low-intensity intervention group).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1210
Est. completion date June 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 79 Years
Eligibility Inclusion Criteria: - 60-79 years of age at pre-screening; - Adequate fluency in Dutch to understand the informed consent and complete questionnaires; - Providing informed consent to all study procedures; - Internet access at home; - Presence of =3 self-reported risk factors for cognitive decline (must contain at least 2 modifiable risk factors and 1 non-modifiable riskfactor). Exclusion Criteria: - Diagnosis of dementia or mild cognitive impairment at baseline (self-reported); - Significant cognitive impairment assessed using the Modified Telephone Interview for Cognitive Status battery (TICSm score<23); - Conditions affecting safe and continuous engagement in the intervention (e.g. under treatment for current malignant diseases, major psychiatric disorders (e.g. major depression, psychosis, bipolar disorder), neurological disorders (e.g. Parkinson's disease, multiple sclerosis), symptomatic cardiovascular disease (e.g. stroke, angina pectoris, heart failure, myocardial infarction), re-vascularization within three months, severe loss of vision, hearing or communicative ability, severe mobility impairment, other conditions preventing co-operation) as judged by the local study nurse or consulted physician at the local study site; - Coincident participation in any other intervention trial at time of pre-screening. - Coincident participation of spouse in FINGER-NL trial.

Study Design


Intervention

Behavioral:
Multidomain lifestyle intervention
A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.

Locations

Country Name City State
Netherlands Alzheimer Center Amsterdam Amsterdam
Netherlands University Medical Center Groningen Groningen
Netherlands Maastricht University Maastricht
Netherlands Radboud University Nijmegen
Netherlands Wageningen Unversity and Research Wageningen

Sponsors (6)

Lead Sponsor Collaborator
Alzheimercentrum Amsterdam Danone Nutricia Research, Maastricht University, Radboud University Medical Center, University Medical Center Groningen, Wageningen University and Research

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other MOCA Montreal Cognitive Assessment, minimum score 0, maximum score 30, with higher scores indicating better cognitive performance baseline
Other Motivation to Change Lifestyle and Health Behavior for Dementia Risk Reduction scale scores range from 27-135, with higher scores indicating greater motivation to change 2 years (measured at baseline, follow-up 1 and follow-up 2)
Primary 2-year change from baseline in global cognitive composite score Global cognitive composite score derived from subtest scores from the Neuropsychological Test Battery (NTB) that includes 15-Word Verbal Learning Test delayed recall (discrete number; 0-15 (higher score means a better outcome)), Digit Symbol Substitution Test 90 seconds (discrete number; 0-90 (higher score means a better outcome)), WAIS digit span backwards (discrete number; 0-14 (higher score means a better outcome)), and semantic fluency (discrete number; 0-no maximum, higher score means a better outcome)). 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary 15-Word Verbal Learning Test delayed recall discrete number; score: 0-15 (higher score means a better outcome) 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Digit Symbol Substitution Test 90 seconds discrete number; 0-90 (higher score means a better outcome) 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Wechsler Adult Intelligence Scale (WAIS) digit span backwards discrete number; 0-14 (higher score means a better outcome) 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Semantic fluency word count in one minute; minimum 0, no maximum, higher score means a better outcome. 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Instrumental activities of daily living using the Amsterdam Instrumental Activity of Daily Living Questionnaire (A-IADL-Q) Total scores range approximately 20-70, higher scores indicate better IADL functioning 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary 5 level EuroQol-5D (EQ-5D-5L) Quality of life, score 0-100, higher scores indicate better quality of life 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary LIfestyle for BRAin health (LIBRA) Modifiable dementia risk using lifestyle for brain health; The score ranges from -5.9 (minimum score) to +12.7 (maximum score), with higher scores meaning a worse outcome (higher dementia risk) 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary grip strength test Scores between 0 to 90 kg can be measured on the Jamar Hand dynamometer, with higher scores indicating better grip strength 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary SQUASH questionnaire METs derived from the Ainsworth's compendium of physical activity will be used to classify physical activity intensity (<1.5METs- sedentary, 1.6-2.9 METs- light, 3.0-5.9METs- moderate, >6.0- vigorous physical activity). 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary LASA Sedentary Behavior Questionnaire Average hours and minutes of sedentary behavior a day, range from 0 to 24 hours. Higher scores (more hours) means a more sedentary behavior. 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Pittsburgh Fatigability Scale Total physical and mental fatigability scores range from 0-50, with higher scores indicating higher fatigability. 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary SARC-F Sarcopenia Questionnaire sarcopenia, scores range from 0 to 10 (i.e. 0-2 points for each component; 0 = best to 10 = worst). 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) Total scale ranges from 24 - 120, higher scores indicate more mindfulness 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Perceived Stress Scale Total score, scale 0 - 40, higher scores indicate more perceived stress 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary MetaMemory in Adulthood (MIA) Sum of Part 1 + Part 2A and B. Part 1: Strategy (scores 10 - 50, higher scores indicate more use of strategies), Part 2A: Subjective memory functioning, scores ranges from 23 - 115, with higher scores indicate better memory self-efficacy and 2B: Locus, scores ranges from 7 - 35, higher scores indicate better perceived personal control over remembering abilities. 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Blood pressure scores range from approximately (for diastolic) 60-120 and (for systolic) 100-180 mmHg, with higher scores indicating higher blood pressure. 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Cholesterol total (healthy level: 125 to 200mg/dL), HDL (healthy level = 40mg/dL or higher), LDL (healthy level = Less than 100mg/dL) + triglycerides (healthy level = less than 150-199 mg/dL) 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Blood glucose HbA1C, scores range from approximately 30-100 mmol/mol, with higher scores indicate higher blood glucose levels. 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Waist circumference measured in cm 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Hip circumference measured in cm 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Height measured in cm 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Weight measured in kg 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Hill-Bone Medication Adherence Scale scores range from 9-26, with lower scores indicating better medication adherence 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary MIND-adjusted Eetscore-FFQ Dutch Healthy Diet Index 2015 score (range 0-160 points, higher scores mean better outcome) and MIND score (range 0-15 points, higher scores mean better outcome), assessed by a short Food Frequency Questionnaire. 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Nutritional intake Change in nutritional intake measured by an online 3-day food diary (assessed by Traqq application), qualitative assessment 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Pittsburg Sleep Quality Index Total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Insomnia severity index The score ranges from 0 (minimum score) to 28 (maximum score), with lower scores indicating a better outcome 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary Lubben Social Network Scale The score ranges from 0 (minimum score) to 30 (maximum score), with higher scores meaning a better outcome (higher level of perceived social support) 2 years (measured at baseline, follow-up 1 and follow-up 2)
Secondary De Jong Gierveldt Loneliness Scale The score ranges from 0 (minimum score) to 6 (maximum score), with higher scores representing a worse outcome (higher loneliness scores) 2 years (measured at baseline and follow-up 2)
Secondary Aß42/40 ratio amyloid-ß (1-42)/(1-40) (pg/mL) 2 years (measured at baseline and follow-up 2)
Secondary p-tau phosphorylated tau (pg/mL) 2 years (measured at baseline and follow-up 2)
Secondary NfL neurofilament light chain (pg/mL) 2 years (measured at baseline and follow-up 2)
Secondary GFAP glial fibrillary acidic protein (pg/mL) 2 years (measured at baseline and follow-up 2)
Secondary BDNF brain-derived neurotrophic factor (pg/mL) 2 years (measured at baseline and follow-up 2)
Secondary Actigraph (Groningen site only) physical activity, sedentary behavior and sleep-wake activity 2 year (measured for 1 week at baseline, follow-up 1 and follow-up 2)
Secondary Physical Activity Record questionnaire (Groningen site only) physical activity, sedentary behavior and sleep-wake activity 2 year (measured for 1 week at baseline, follow-up 1 and follow-up 2)
See also
  Status Clinical Trial Phase
Completed NCT03228446 - The Effects of Attentional Filter Training on Working Memory N/A
Completed NCT04033419 - Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer Phase 2
Terminated NCT05199142 - A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline Phase 1
Active, not recruiting NCT05290233 - Time Restricted Eating Plus Exercise for Weight Management N/A
Terminated NCT03337282 - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Unknown status NCT00696514 - Vitamin B12 and Folic Acid Supplementation for Preventing Fractures in Elderly People Phase 1
Completed NCT00110604 - The Effect of Folic Acid on Atherosclerosis, Cognitive Performance and Hearing N/A
Recruiting NCT06245005 - Preoperative Cognitive Reserve in Older Surgical Patients: A Feasibility Study
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Active, not recruiting NCT05586750 - Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy Phase 4
Completed NCT04386902 - Evaluation of Cognitive State Using Neurosteer EEG System
Recruiting NCT06070818 - Healthy Body & Mind Program for Older Adults Living With Osteoarthritis and Cognitive Decline N/A
Completed NCT01669915 - A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline N/A
Completed NCT02814526 - Exercise in Adults With Mild Memory Problems N/A
Not yet recruiting NCT05928078 - A Home-based e-Health Intervention in the Elderly: MOVI-ageing N/A
Not yet recruiting NCT06252376 - Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD N/A
Recruiting NCT06318377 - Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals N/A
Recruiting NCT03839784 - Building a Platform for Precision Anesthesia in the Geriatric Surgical Patient
Completed NCT04537728 - My Healthy Brain: Preserving and Promoting Brain Health Through Evidence-based Practices N/A
Active, not recruiting NCT03370796 - Group Reminiscence Therapy for Elderly People With Cognitive Decline in Institutional Context N/A